Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thatcher

Showing results (241-250 of 289) with videos related to

Pageof 29
Sort By:
Behring Institute Mitteilungen|August 1, 1988
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM Bronchud, J H Scarffe, N Thatcher, et al.
Gene Therapy|September 25, 1998
Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitroI Hickson, L J Fairbairn, N Chinnasamy, et al.
International Journal of Cancer|January 11, 2000
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenograftsM R Middleton, J Kelly, N Thatcher, et al.
British Journal of Cancer|December 1, 1987
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM H Bronchud, J H Scarffe, N Thatcher, et al.
International Journal of Cancer|September 30, 1992
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC)T Cerny, M F Fey, R Oppliger, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancerJ P Braybrooke, M Ranson, C Manegold, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working PartyN Thatcher, P I Clark, D B Smith, et al.
British Journal of Cancer|August 1, 1993
A phase I study of intravenous bryostatin 1 in patients with advanced cancerJ Prendiville, D Crowther, N Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II studyH von der Maase, P Geertsen, N Thatcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2016
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancerL Paz-Ares, M A Socinski, J Shahidi, et al.
Pageof 29

Showing results (241-250 of 289) with videos related to

Sort By:
Pageof 29
Behring Institute Mitteilungen|August 1, 1988
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM Bronchud, J H Scarffe, N Thatcher, et al.
Gene Therapy|September 25, 1998
Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitroI Hickson, L J Fairbairn, N Chinnasamy, et al.
International Journal of Cancer|January 11, 2000
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenograftsM R Middleton, J Kelly, N Thatcher, et al.
British Journal of Cancer|December 1, 1987
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM H Bronchud, J H Scarffe, N Thatcher, et al.
International Journal of Cancer|September 30, 1992
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC)T Cerny, M F Fey, R Oppliger, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancerJ P Braybrooke, M Ranson, C Manegold, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working PartyN Thatcher, P I Clark, D B Smith, et al.
British Journal of Cancer|August 1, 1993
A phase I study of intravenous bryostatin 1 in patients with advanced cancerJ Prendiville, D Crowther, N Thatcher, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II studyH von der Maase, P Geertsen, N Thatcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2016
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancerL Paz-Ares, M A Socinski, J Shahidi, et al.
Pageof 29